Experienced in Osteosclerosis Autosomal Dominant

Ashok Vellodi

Great Ormond Street Hospital For Children NHS Foundation Trust, 
London, ENG, GB 
Experienced in Osteosclerosis Autosomal Dominant
Great Ormond Street Hospital For Children NHS Foundation Trust, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Ashok Vellodi practices in London, United Kingdom. Mr. Vellodi is rated as an Experienced expert by MediFind in the treatment of Osteosclerosis Autosomal Dominant. His top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Farber Lipogranulomatosis, Sudden Infant Death Syndrome (SIDS), and Gaucher Disease.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Osteosclerosis Autosomal Dominant.

Gender
Male

Locations

Great Ormond Street Hospital For Children NHS Foundation Trust, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy
A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
View 2 Less Clinical Trials

22 Total Publications

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Journal: Orphanet journal of rare diseases
Published: January 12, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vellodi's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile